Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2023-12-20 00:00:00 ET · period of report 2023-12-18 · accession 0001610717-23-000416 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2023-12-20 | 2023-12-18 | RVMD | Anders Jack | CFO | S - Sale | $25.90 | -1,775 | 76.4K | -2% | -$46.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-18 | S | D | 1,775 | $25.90 | 76,416 | D | — | — | (F2) Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. (F3) This transaction was executed in multiple trades in prices ranging from $25.9017 to $25.9385, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F4) Includes 37,326 RSUs. |